DBVT - DBV Technologies S.A.
| Previous Close | 7.80 |
| Open | 7.91 |
| Bid | 8.00 x 900 |
| Ask | 8.01 x 1000 |
| Day's Range | 7.88 - 8.10 |
| 52 Week Range | 3.60 - 16.19 |
| Volume | 270,234 |
| Avg. Volume | 368,375 |
| Market Cap | 755M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.54 |
- GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des.
- GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité.
- GlobeNewswire
DBV Technologies to Present at the Stifel 2019 Healthcare Conference
Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock.
- Insider Monkey
Here’s What Hedge Funds Think About DBV Technologies SA – ADR (DBVT)
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
- GlobeNewswire
DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019
Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates.
- GlobeNewswire
DBV Technologies Announces Closing of Global Offering
Montrouge, France, October 15, 2019 DBV Technologies Announces Closing of Global Offering DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock.
- GlobeNewswire
DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its previously announced global offering reserved to specified categories of investors have exercised in full their option to purchase 1,368,667 additional ordinary shares in the form of 2,737,334 American Depositary Shares (“ADSs”), at an offering price of $6.59 per ADS, before deducting commissions and estimated offering expenses (the “Option”). Each ADS represents the right to receive one-half of one ordinary share, and the offering price of $6.59 per ADS corresponds to a price of €12.04 per ordinary share (on the basis of an exchange rate of $1.0945 = €1.00).
- GlobeNewswire
DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the pricing of a global offering of an aggregate of 9,484,066 ordinary shares reserved to specified categories of investors in (i) an offering of 7,914,622 ordinary shares in the form of 15,829,244 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe at a public offering price of $6.59 per ADS (on the basis of an exchange rate of $1.0945 = €1.00) and (ii) a private placement of 1,569,444 ordinary shares in Europe (including France) at a public offering price of €12.04 per ordinary share. The price at which the ordinary shares (including in the form of ADSs) will be sold in the global offering is equal to the volume weighted-average of the trading price of the Company’s ordinary shares on Euronext Paris on the trading day prior to pricing of the global offering less a discount of 14.9%.
- GlobeNewswire
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its intention to issue and sell, subject to market conditions, up to $125.0 million of new ordinary shares, which may be in the form of American Depositary Shares (“ADSs”), by means of a global offering, the subscription of which is reserved to specified categories of investors. The global offering will be comprised of an offering of ordinary shares in the form of ADSs in the United States, Canada and certain other countries outside of Europe and a private placement of ordinary shares in Europe (including France).
- GlobeNewswire
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for its investigational Viaskin® Peanut immunotherapy for the treatment of peanut-allergic children ages 4 to 11 years. Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts.
- Simply Wall St.
Does Market Volatility Impact DBV Technologies S.A.'s (EPA:DBV) Share Price?
Anyone researching DBV Technologies S.A. (EPA:DBV) might want to consider the historical volatility of the share...
- Benzinga
Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front
Aimmune Therapeutics Inc (NASDAQ: AIMT )'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. ...
- Benzinga
DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies
DBV said late Wednesday it has submitted its Biologic License Application, or BLA, for Viaskin Peanut, which is being evaluated for treating peanut-allergic children ages 4-11. Viaskin Peanut, an epicutaneous immunotherapy, is DBV's proprietary investigational platform designed to leverage the skin to activate the immune system and induce desensitization to allergens. In December 2018, the company voluntarily withdrew its prior BLA submission after the FDA communicated the need for additional data on manufacturing procedures and controls.
- GlobeNewswire
DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years. Viaskin Peanut is the Company’s lead product candidate based on epicutaneous immunotherapy (EPIT®).
- GlobeNewswire
DBV Technologies Reports First Half 2019 Financial Results
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The interim financial report is available on the Investor Relations section of the Company’s website, www.dbv-technologies.com/investor-relations/. First half 2019 financial statements were subject to a limited review by the Company’s external auditors.
- Simply Wall St.
If You Had Bought DBV Technologies (EPA:DBV) Stock Three Years Ago, You'd Be Sitting On A 71% Loss, Today
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
- GlobeNewswire
Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report
AMF REGULATED INFORMATIONMontrouge, France, July 18, 2019 Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report DBV Technologies.
- Motley Fool
Here's Why Aimmune Therapeutics Fell 7% Today
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
- GlobeNewswire
DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Pharis Mohideen, M.D., as its Chief Medical Officer (CMO), effective July 22, 2019. Dr. Mohideen will serve as a member of the Executive Committee and report to Daniel Tassé, Chief Executive Officer of DBV Technologies.
- Zacks
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
